8-K: BridgeBio's Infigratinib Achieves Phase 3 Success in Achondroplasia

BridgeBio Pharma announced positive Phase 3 topline results for oral infigratinib, showing statistically significant improvements in height velocity and body proportionality in children with achondroplasia.

Summary

• The PROPEL 3 global Phase 3 pivotal study of oral infigratinib in children with achondroplasia successfully met its primary endpoint of change from baseline in annualized height velocity (AHV) at Week 52 (p<0.0001).
• The change from baseline in AHV was superior to placebo at Week 52, with a mean treatment difference of +2.10 cm/year (LS mean of +1.74 cm/year).
• In a pre-specified exploratory analysis, oral infigratinib achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia, demonstrating an LS mean treatment difference of -0.05 (p<0.05) in children younger than 8 years old (>50% of participants).
• The study also successfully met the key secondary endpoint of change from baseline in height Z-score (achondroplasia reference population) at Week 52 (p<0.0001), with an LS mean increase on the treatment arm of +0.41 SD.
• Oral infigratinib was well tolerated, with no discontinuations or serious adverse events related to the study drug, and only 3 cases (4%) of mild, transient hyperphosphatemia that did not require dose reduction or discontinuation.
• No adverse events associated with inhibition of FGFR1 or 2 (e.g., retinal or corneal) or CNP analogues were observed.
• BridgeBio plans to submit New Drug Application (NDA) and Marketing Authorization Application (MAA) for infigratinib in achondroplasia in the second half of 2026.
• Given the strength of these data, BridgeBio plans to accelerate the development of oral infigratinib in hypochondroplasia and is enrolling the observational run-in for the Phase 3 trial.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as highly positive due to the statistically significant and 'best-in-class' results across multiple key endpoints, including the first-ever improvement in body proportionality, coupled with a strong safety profile and clear regulatory path forward.

Positives

• PROPEL 3 successfully met the primary endpoint of change from baseline in annualized height velocity (AHV) at Week 52 (p<0.0001).
• Change from baseline in AHV was superior to placebo at Week 52, with a mean treatment difference of +2.10 cm/year (LS mean +1.74 cm/year).
• Achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia in children younger than 8 years old (LS mean treatment difference of -0.05, p<0.05).
• Successfully met the key secondary endpoint of change from baseline in height Z-score (achondroplasia reference population) at Week 52 (p<0.0001), with an LS mean increase on the treatment arm of +0.41 SD.
• Oral infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug.
• Only 3 cases (4%) of hyperphosphatemia were reported, all mild, transient, asymptomatic, and not requiring dose reductions or discontinuations.
• No adverse events associated with inhibition of FGFR1 or FGFR2 (e.g., retinal or corneal) or CNP analogues were observed.
• Infigratinib is the only therapeutic option in development for achondroplasia to have Breakthrough Therapy Designation from the FDA.
• The infigratinib arm achieved the highest LS mean absolute AHV reported to date in a randomized trial in achondroplasia (5.96 cm/year versus 4.22 cm/year on placebo).
• The LS mean treatment difference of +0.32 SD in height Z-score is the largest difference observed in a randomized trial in achondroplasia.

Risks

• Initial and ongoing data from preclinical studies and clinical trials may not be indicative of final data.
• The potential size of the target patient populations for product candidates may not be as large as anticipated.
• Difficulties may arise with enrollment in clinical trials.
• Adverse events may be encountered in clinical trials.
• Future regulatory filings, approvals, and/or sales are not guaranteed.
• The FDA or other regulatory agencies may not agree with regulatory approval strategies, components of filings, or the sufficiency of data submitted.
• The continuing success of collaborations is not assured.
• The ability to obtain additional funding may be challenging.
• Potential volatility in the company's share price.
• Impacts of current macroeconomic and geopolitical events, including hostilities in Ukraine and in Israel and the Gaza Strip, increasing rates of inflation, and changing interest rates, on overall business operations and expectations.

Future Outlook

BridgeBio plans to submit New Drug Application (NDA) and Marketing Authorization Application (MAA) for infigratinib in achondroplasia in the second half of 2026. The company also intends to accelerate the development of infigratinib for hypochondroplasia, with enrollment ongoing for the observational run-in for its Phase 3 trial, and continues an ongoing clinical trial for newborn to <3 year old age groups in achondroplasia (PROPEL Infant & Toddler trial).

Management Comments

• "Infigratinib is the first oral therapy designed to target FGFR3 and directly address the underlying cause of achondroplasia. In the broadest age range studied to date, oral infigratinib has demonstrated the highest and most significant improvement in annualized growth velocity, along with the first statistically significant improvement in body proportionality, in children aged 3 to 8 years, reported for any therapy approved or in development for this condition. Taken together, these best-in-class results highlight the transformative potential for infigratinib to address aspects of achondroplasia beyond linear height, and with a product administered orally." Ravi Savarirayan, M.D., Ph.D., Global Lead Investigator for PROPEL 3.
• "There remains a significant unmet need for therapeutic options that are effective, practical, and less invasive for children living with achondroplasia. The PROPEL 3 data support the potential of an oral medicine directly targeting FGFR3 overactivity to address important clinical needs, while fitting into daily life for families who are seeking a non-injectable option. These results represent meaningful progress for those who have been waiting for a better approach, and we look forward to advancing this program towards global submissions." Daniela Rogoff, M.D., Chief Medical Officer, Skeletal Dysplasia of BridgeBio.
• "Today's announcement represents another milestone in achondroplasia research and, pending regulatory review, expands available care to include an oral therapeutic option, offering individuals and families additional choice as they consider their healthcare goals and preferences. BridgeBio's commitment to engaging with and learning from the dwarfism community reflects a focus on listening to lived experience and recognizing diverse priorities in shaping research efforts. Within this context, the observed improvement in body proportionality with one year of treatment in the PROPEL 3 study is an outcome that individuals and families have identified as meaningful, may be relevant to physical function, and continues to be evaluated to understand its broader significance." Michael Hughes, Chair of the Biotech Industry Liaison Committee at Little People of America.

Industry Context

StockSavvy.ai notes that these positive Phase 3 results for oral infigratinib position BridgeBio as a significant contender in the achondroplasia treatment landscape. The achievement of statistically significant improvements in both annualized height velocity and, notably, body proportionality, with a well-tolerated oral formulation, addresses a critical unmet need for less invasive and more comprehensive therapeutic options. This could potentially differentiate infigratinib from existing or other pipeline therapies, which may be injectable or have different safety profiles.

Comparison to Industry Standards

• Infigratinib demonstrated the "highest and most significant improvement in annualized growth velocity" reported for any therapy approved or in development for achondroplasia in children aged 3 to 8 years.
• Achieved the "first statistically significant improvement in body proportionality" against placebo in achondroplasia in children younger than 8 years old.
• The LS mean absolute AHV of 5.96 cm/year on the infigratinib arm is the "highest LS mean absolute AHV reported to date in a randomized trial in achondroplasia" compared to 4.22 cm/year on placebo.
• The LS mean treatment difference of +0.32 SD in height Z-score is the "largest difference observed in a randomized trial in achondroplasia," with the LS mean change from baseline on the treatment arm of +0.41 SD being the "largest improvement observed on a treatment arm in a randomized trial for achondroplasia."
• The LS mean decrease of -0.05 in upper-to-lower body proportionality in the overall population is the "largest reduction observed in a treatment arm in a randomized achondroplasia trial."

Stakeholder Impact

• Shareholders: Positive impact due to successful Phase 3 results, potential for regulatory approval, and expanded market opportunities.
• Patients (Children with Achondroplasia): Significant positive impact by offering a potentially transformative, well-tolerated, and non-injectable oral therapeutic option that addresses both height velocity and body proportionality.
• Families: Provides a less invasive and more practical treatment option that fits into daily life.
• Regulatory Authorities: Provides new data for a condition with unmet needs, potentially leading to a new approved therapy.

Next Steps

• Meet with regulatory authorities to discuss plans for submission of a New Drug Application (NDA) and Marketing Authorization Application (MAA) for infigratinib in the second half of 2026.
• Accelerate the development of infigratinib for hypochondroplasia, with enrollment ongoing for the observational run-in for the Phase 3 trial.
• Continue the ongoing clinical trial of infigratinib for the newborn to <3 year old age groups in achondroplasia (PROPEL Infant & Toddler trial).
• Explore the potential of infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia, and other skeletal dysplasia conditions.

Key Dates

Recommendation

The positive Phase 3 topline results for oral infigratinib in achondroplasia are highly significant, demonstrating statistically superior improvements in both annualized height velocity and, for the first time, body proportionality, with an excellent safety profile. This positions infigratinib as a potential best-in-class oral therapy for a condition with high unmet medical need. The planned NDA and MAA submissions in the second half of 2026, coupled with Breakthrough Therapy Designation, indicate a clear and accelerated path to market. These strong clinical outcomes significantly de-risk the program and enhance BridgeBio's long-term growth prospects, making it a compelling investment opportunity.

Keywords

BridgeBio Pharma, BBIO, Infigratinib, Achondroplasia, Phase 3, Clinical Trial, Topline Results, Skeletal Dysplasia, FGFR3, Breakthrough Therapy Designation, Orphan Drug, Rare Pediatric Disease, Biopharmaceutical, Genetic Conditions, Drug Development